DPDoctor's PassportEducation
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
RapidMLAMSRAFoundationGP

Contraceptive interactions with enzyme-inducing medicines

Essential points for quick revision.

!
An interaction can create immediate pregnancy risk

Unprotected intercourse during enzyme induction or within 28 days after it ends can represent contraceptive failure for CHC, POP, implant and oral emergency contraception.

Action: Reconstruct medicine, contraception and intercourse dates today, offer copper-IUD emergency contraception first, consider double-dose levonorgestrel only when needed, and establish an unaffected ongoing method.

Synopsis

Prevent contraceptive failure by recognising hepatic enzyme induction, selecting unaffected methods, managing short and long courses, modifying emergency contraception and separating induction from other important interactions.

  • Enzyme inducers increase hepatic metabolism of contraceptive steroids and can reduce effectiveness of combined pills, patch and ring, progestogen-only pills, etonogestrel implant and oral emergency contraception.
  • Copper IUD, levonorgestrel IUD and depot medroxyprogesterone acetate are not reduced by hepatic enzyme induction and are the preferred reliable options when acceptable.
  • Important inducers include carbamazepine, phenytoin, phenobarbital, primidone, oxcarbazepine, rifampicin, rifabutin and St John’s wort; treat topiramate as a potential inducer regardless of dose under current CoSRH caution.

Key red flags

A patient taking a teratogenic medicine such as topiramate or some antiseizure drugs without reliable unaffected contraception needs urgent specialist coordination before exposure or pregnancy occurs.

Investigation priorities

01
Exact medicine reconciliationFirst step

Identify the inducer, dose, indication, duration and start or stop date before contraceptive failure occurs.

Management branches

First-line unaffected optionsChoose IUD or DMPA

A patient will use an enzyme-inducing medicine for a prolonged or uncertain duration.

  1. Confirm the exact inducer, teratogenic risk, expected duration, current contraception, recent intercourse and medical eligibility.
  2. Offer copper IUD, LNG-IUD or standard-schedule DMPA as reliable methods unaffected by induction, comparing bleeding, procedure, bone and fertility-return effects.

Key medicines

Depot medroxyprogesterone acetate during enzyme inductionAdminister 150 mg intramuscularly or 104 mg subcutaneously every 13 weeks using the standard schedule; no dose increase is required for hepatic enzyme induction.
Levonorgestrel emergency contraception with enzyme inductionIf copper-IUD emergency contraception is declined or unsuitable, give levonorgestrel 3 mg orally once during current induction or within 28 days of stopping, repeating if vomiting occurs within three hours.
Open full textbook Answer 2 questions
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom